Linda Higgins

Linda Higgins, Ph.D., currently serves as Senior Vice President of Research, External Innovation at Gilead Sciences, Inc. Dr. Higgins joined Gilead in 2010 and in her first nine years led Biology, leading a significant expansion of the therapeutic area scope and capabilities of the department.

Prior to joining Gilead, Dr. Higgins previously served as the President & CEO of InteKrin Therapeutics and as Head of Research at Scios, Inc., a Johnson & Johnson company, where she provided leadership for drug discovery, preclinical development, and translational medicine. Dr. Higgins obtained her BA degree in Behavioral Physiology from Kenyon College and her Ph.D. in Neuroscience from the University of California, San Diego School of Medicine, and conducted her post-doctoral research in Molecular Genetics at the Howard Hughes Medical Institute at the University of California, Berkeley. Dr. Higgins currently serves on the Supervisory Board of Galapagos and the Board of Directors of Tizona Therapeutics.